Role of Helicobacter pylori Eradication in Patients with Functional Dyspepsia Using Proton Pump Inhibitor and Potassium Competitive Acid Blocker Based Regimens in Eastern India: A Single Centre Randomized Controlled Trial

Brief Summary (for Clinical Trials Registry of India CTRI):

Functional dyspepsia is common in India, affecting nearly thirty percent of adults. It is characterized by postprandial fullness, early satiation, epigastric pain, or epigastric burning without any identifiable organic cause on routine evaluation. The role of Helicobacter pylori infection in causing symptoms of functional dyspepsia remains controversial. Some studies and meta analyses have shown improvement in symptoms after eradication therapy, while others have shown little or no benefit. Because of these conflicting findings and limited data from India, the benefit of eradication therapy in patients with functional dyspepsia is still uncertain.

This study aims to evaluate whether eradication of Helicobacter pylori provides additional symptomatic benefit compared with standard medical treatment in patients with Helicobacter pylori positive functional dyspepsia. In this prospective randomized controlled trial, patients will receive either Proton Pump Inhibitor based eradication therapy, Potassium Competitive Acid Blocker based eradication therapy, or standard medical treatment. The study will compare improvement in dyspeptic symptoms and eradication rates among the treatment groups. The results may help clarify the role of Helicobacter pylori eradication in the management of functional dyspepsia in the Indian population.